Table 1.
Demographic, biochemical, molecular, and histological profiles of patients at baseline
| All patients | HCV RNA (kIU/ml) at week 4 | P-value† | ||
|---|---|---|---|---|
| <500 | ≥500 | |||
| Patients, n | 132 | 108 | 24 | |
| Gender, male/female (% male) | 81/51 (61) | 68/40 (63) | 13/11 (54) | 0.423‡ |
| Age (years)a | 56.4 ± 12.2 | 56.0 ± 12.2 | 57.8 ± 12.2 | 0.536§ |
| Weight (kg)a | 61.5 ± 12.6 | 62.0 ± 13.1 | 58.6 ± 9.5 | 0.257§ |
| Naive/re-treatment | 119/13 | 98/10 | 21/3 | 0.704# |
| Fibrosis staging, n (F1/F2/F3/F4) | 57/26/8/1 | 48/22/6/1 | 9/4/2/0 | 0.881‡ |
| Grading, n (A0-1/A2/A3) | 52/38/2 | 44/31/2 | 8/7/0 | 0.868‡ |
| Genotype, 1/2 (% genotype 1) | 17/115 (13) | 15/93 (14) | 2/22 (8) | 0.737# |
| HCV RNA (kIU/ml)b | 285 (46–1620) | 130 (37–1006) | 1350 (360–3060) | <0.001¶ |
| ALT (IU/l)b [7–42]c | 66 (35–117) | 64 (36–119) | 69 (31–109) | 0.571¶ |
| γ-GTP (IU/l)b [5–50]c | 45 (24–92) | 54 (26–97) | 33 (21–49) | 0.014¶ |
| Neutrophil count (/μl)a [1000–7500]c | 2844 ± 1036 | 2898 ± 1042 | 2615 ± 996 | 0.230§ |
| Hemoglobin (g/dl)a [13.5–17.5]c | 14.0 ± 1.2 | 14.1 ± 1.2 | 14.0 ± 1.4 | 0.751§ |
| Platelet count (103/μl)a [150–400]c | 175 ± 63 | 179 ± 66 | 155 ± 40 | 0.089§ |
ALT alanine aminotransferase, γ-GTP gamma glutamyl transpeptidase
†Comparison between groups according to HCV RNA at week 4
‡Chi-square test
#Fisher’s exact test
§Unpaired-t test
¶Mann–Whitney U-test
Data are a mean ± SD or b median (interquartile range), c normal range